Đang chuẩn bị liên kết để tải về tài liệu:
Lower PRDM2 expression is associated with dopamine-agonist resistance and tumor recurrence in prolactinomas

Dopamine agonists (DAs) are the first-line treatment for prolactinomas, which account for 25–30% of functioning pituitary adenomas, and bromocriptine (BRC) is the only commercially available DAs in China. However, tumors are resistant to therapy in 5–18% of patients. |